Albert Bourla, Pfizer CEO (Evan Vucci, AP Images)
Pfizer CEO points to IRA as a factor that made Seagen an attractive target
One of the reasons Pfizer sought to purchase Seagen, as part of a $43 billion deal announced this morning, is that the Seattle-based biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
